<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pci Biotech Holding Asa — News on 6ix</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1</link>
<description>Latest news and press releases for Pci Biotech Holding Asa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Feb 2026 12:17:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pci-biotech-holding-asa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5518ebeedb30cb6f78f11.webp</url>
<title>Pci Biotech Holding Asa</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1</link>
</image>
<item>
<title>Notice of Extraordinary General Meeting, proposed company dissolution and delisting</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/notice-of-extraordinary-general-meeting-proposed-company-dissolution-and-delisting</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/notice-of-extraordinary-general-meeting-proposed-company-dissolution-and-delisting</guid>
<pubDate>Mon, 23 Feb 2026 12:17:00 GMT</pubDate>
<description>Oslo, Norway 23 February 2026 – An extraordinary general meeting of PCI Biotech Holding ASA (‘PCI Biotech’ or ‘Company’) will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET). The proposed resolutions include company dissolution and delisting from Euronext Oslo Børs. The Board of Directors’ proposed resolution to dissolve PCI Biotech is made as there is no longer any operational activity in the Company, nor is it expected that it will resu</description>
</item>
<item>
<title>PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-initiates-a-process-to-evaluate-the-opportunity-for-a-structured-wind-up-process</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-initiates-a-process-to-evaluate-the-opportunity-for-a-structured-wind-up-process</guid>
<pubDate>Thu, 29 Jan 2026 16:50:00 GMT</pubDate>
<description>Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic alternatives. This evaluation has now been concluded. Following careful consideration of the PCI Biotech group’s circumstances, the Board has resolved to initiate a process to evaluate the opportunity for a structured wind-up. The liquidity position of the PCI Biotech group remains critical, cas</description>
</item>
<item>
<title>PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-announces-discontinuation-of-randd-operations-and-continues-evaluation-of-future-options</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-announces-discontinuation-of-randd-operations-and-continues-evaluation-of-future-options</guid>
<pubDate>Thu, 08 Jan 2026 13:10:00 GMT</pubDate>
<description>Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued. In recent months, various strategic alternatives have been explored, and this process continues. The evaluati</description>
</item>
<item>
<title>PCI Biotech update</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-update</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-update</guid>
<pubDate>Thu, 23 Oct 2025 08:35:00 GMT</pubDate>
<description>Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations. Reference is made to the company’s announcements dated 18th August 2025 and 25th September 2025, as well as the interim report for the first half of 2025 published on 29th August 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement withou</description>
</item>
<item>
<title>PCI Biotech update on future operations</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-update-on-future-operations</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-update-on-future-operations</guid>
<pubDate>Thu, 25 Sep 2025 13:36:00 GMT</pubDate>
<description>Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the discontinuation of further development of the PCL technology. The decision was based on insufficient progress, which extended project timelines and increased resource requirements, elevating the overall project risk to an unacceptable level. Consequently, PCI Biotech decided to discontinue f</description>
</item>
<item>
<title>PCI Biotech half-year interim 2025 report</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-half-year-interim-2025-report</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-half-year-interim-2025-report</guid>
<pubDate>Fri, 29 Aug 2025 05:00:00 GMT</pubDate>
<description>Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achievin</description>
</item>
<item>
<title>PCI Biotech: Invitation to first half 2025 results presentation and corporate update</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-invitation-to-first-half-2025-results-presentation-and-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-invitation-to-first-half-2025-results-presentation-and-corporate-update</guid>
<pubDate>Tue, 26 Aug 2025 14:15:00 GMT</pubDate>
<description>Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time). The presentation will be held in Norwegian as a live webcast available through www.pcibiotech.com. There will be a Q&A session at the end of the presentation. Please submit questions to post@pcibiotech.no prior to the webcast. It will be possible to post written questions through the webcast console</description>
</item>
<item>
<title>PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-announces-discontinuation-of-development-of-the-pcl-technology-and-evaluation-of-future-operations</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-announces-discontinuation-of-development-of-the-pcl-technology-and-evaluation-of-future-operations</guid>
<pubDate>Mon, 18 Aug 2025 18:40:00 GMT</pubDate>
<description>Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing. Today’s decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk-reducing milestone for further development. Following the progre</description>
</item>
<item>
<title>PCI BIotech: Disclosure of voting rights for Chair of the Board</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-disclosure-of-voting-rights-for-chair-of-the-board</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/pci-biotech-disclosure-of-voting-rights-for-chair-of-the-board</guid>
<pubDate>Tue, 20 May 2025 20:09:00 GMT</pubDate>
<description>Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 22 May 2025. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 3,957,330 additional shares. In total, Mr.</description>
</item>
<item>
<title>Notice of Annual General Meeting 2025</title>
<link>https://6ix.com/company/pci-biotech-holding-asa-1/news/notice-of-annual-general-meeting-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/pci-biotech-holding-asa-1/news/notice-of-annual-general-meeting-2025-4</guid>
<pubDate>Wed, 30 Apr 2025 08:00:00 GMT</pubDate>
<description>Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website www.pcibiotech.com. For further information, please contact: Ronny Skuggedal, CEO/CFO, E-mail: rs@pcibiotech.noOffice: +47 67 11 5</description>
</item>
</channel>
</rss>